In a human clinical trial of PD-1 checkpoint inhibitor treatment of two types of squamous cell carcinoma (Prat et al., 2017), high expression of TSK-specific genes ITGB1 and PLAU correlated with significantly reduced progression-free survival (p = 0.0137) (Figure 6I). This evidence concerns the gene PDCD1 and squamous cell carcinoma.